Why has UBS raised Aurobindo Pharma's target price to ₹1,800?
Brokerage Update
UBS has increased its target price on Aurobindo Pharma to ₹1,800 from ₹1,400 while maintaining a Neutral recommendation. The brokerage acknowledges improving growth visibility but believes much of the upside is already reflected in the stock price.
UBS has increased its target price on Aurobindo Pharma to ₹1,800 from ₹1,400 while maintaining a Neutral recommendation. The brokerage acknowledges improving growth visibility but believes much of the upside is already reflected in the stock price.
Get Professional Market Insights
Nifty Tips
Nifty Tips
Key highlights from UBS
- Target Price raised to ₹1,800 from ₹1,400.
- Recommendation maintained at Neutral.
- Growth profile continues to improve across business segments.
- Revenue CAGR expected at approximately 13% between FY26-FY29.
- EBITDA CAGR expected at approximately 14% between FY26-FY29.
- EPS estimates increased by 7-9% for FY27-FY29.
What is driving the positive outlook?
According to UBS, Aurobindo Pharma's diversification strategy is creating a broader growth runway. Expansion beyond traditional generic pharmaceuticals, increasing product depth and improving business mix are expected to support stronger earnings growth over the next few years.
Growth Expectations
• Revenue CAGR (FY26-FY29): ~13%
• EBITDA CAGR (FY26-FY29): ~14%
• EPS Upgrades: 7-9% for FY27-FY29
• Revenue CAGR (FY26-FY29): ~13%
• EBITDA CAGR (FY26-FY29): ~14%
• EPS Upgrades: 7-9% for FY27-FY29
Why is UBS still Neutral?
Despite acknowledging stronger fundamentals, UBS believes the stock has already priced in a substantial portion of the expected growth. As a result, the brokerage sees the risk-reward equation as relatively balanced at current levels.
Brokerage View
Improving business outlook ✔️
Higher earnings estimates ✔️
Valuation already reflects much of the optimism ⚠️
Therefore, the recommendation remains Neutral.
Improving business outlook ✔️
Higher earnings estimates ✔️
Valuation already reflects much of the optimism ⚠️
Therefore, the recommendation remains Neutral.
What should investors monitor?
- US generics business performance.
- Margin expansion trends.
- New product launches.
- Specialty and differentiated product contribution.
- Execution of diversification strategy.
- Sustained earnings upgrades in upcoming quarters.
Investor Takeaway
Indian-Share-Tips.com Nifty Expert Gulshan Khera, CFP®, who is also a SEBI Regd Investment Adviser, observes that UBS's target price revision highlights growing confidence in Aurobindo Pharma's earnings trajectory. However, the continuation of a Neutral rating suggests that future stock performance may depend more on execution and earnings delivery than on valuation re-rating alone.
Indian-Share-Tips.com Nifty Expert Gulshan Khera, CFP®, who is also a SEBI Regd Investment Adviser, observes that UBS's target price revision highlights growing confidence in Aurobindo Pharma's earnings trajectory. However, the continuation of a Neutral rating suggests that future stock performance may depend more on execution and earnings delivery than on valuation re-rating alone.
Need Daily Market Guidance?
Bank Nifty Tips
Bank Nifty Tips
Written by Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
Read Free content at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
